Directorate Change

Creo Medical Group plc (AIM: CREO), a medical device company focused on the emerging field of minimally invasive surgical endoscopy for pre-cancer and cancer patients, announces that John Bradshaw, Senior Independent Non-Executive Director, has stood down from the Board with immediate effect, in-line with the previous announcements of his planned retirement from the role having served as a Non-Executive Director since IPO in 2016.

As reported in the 2024 AGM statement, John had informed the Board of his intention to retire ahead of the 2025 AGM. John has remained in his role to ensure stability during the last 12 months whilst the Company transitioned to its new leadership model.

Ivonne Cantu, Non-executive Director of Creo, has agreed to act as interim Audit Committee chair whilst the Company identifies an appropriate appointment to the Board as replacement for the Audit Committee chair role. John will be available to support Ivonne during this interim role and to the future incoming Audit Committee chair to ensure an orderly handover.

Furthermore, Brent Boucher will move into the role of Remuneration Committee chair in place of Ivonne Cantu. Ivonne will continue to remain a member of the Remuneration Committee.

Kevin T. Crofton, Non-Executive Chairman, commented:

"I would like to thank John for his service to the Company. John has helped guide and lead Creo with professionalism and pragmatism during his nine-year tenure from IPO, and has provided much welcome support to me and the team as we've continued to build the Company's governance framework."